3 hurdles healthcare AI should strive to clear this year

Want to see AI in healthcare? Look anywhere. Want to see AI underperforming in healthcare? The same directive applies.

The challenges facing the ubiquitous if still overhyped technology get a tidy untangling in Dataconomy by Ralph Tkatchuk, a freelance data security consultant. He points out three particular areas in which healthcare AI in its various iterations needs further maturing and more training:

1. Digitizing and consolidating data. Noting how hard it can be to marshal datasets stored in widely dispersed siloes that don’t speak to one another, Tkatchuk suggests stakeholders work harder at finding ways to “improve data consolidation and digitization so that medical data can be properly processed and analyzed by AI.”

2. Updating regulations. Privacy and confidentiality laws are good and necessary, but ensuring strict compliance can unfortunately thwart AI developers and implementers who might otherwise be able to drive great value into U.S. healthcare. “Regulatory bodies must implement rules that will help protect identities and allow healthcare providers to acquire high-quality data to allow their AI technologies to process data,” Tkatchuk writes. “Likewise, medical institutions must do their due diligence to comply with these regulations and be accountable in how they obtain patient data.”

3. Involving Humans. From patients wary about machines directing their care to providers worried about getting “replaced by robots,” concerns continue to swirl around the very concept of AI in healthcare. Overcoming such anxieties “is key to building an AI-driven healthcare system,” Tkatchuk asserts. “There must be a full understanding that AI only serves to augment the diagnostic capabilities of healthcare practitioners. This will encourage everyone to embrace AI-assisted medical practices.”

Read the whole thing at Dataconomy:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.